PULM Stock - Pulmatrix, Inc.
Unlock GoAI Insights for PULM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.81M | $7.30M | $6.07M | $5.17M | $12.63M |
| Gross Profit | $640,000 | $-8,220,000 | $-12,169,000 | $-10,213,000 | $12.63M |
| Gross Margin | 8.2% | -112.6% | -200.4% | -197.6% | 100.0% |
| Operating Income | $-9,763,000 | $-14,740,000 | $-18,947,000 | $-20,167,000 | $-9,862,000 |
| Net Income | $-9,559,000 | $-14,121,000 | $-18,836,000 | $-20,171,000 | $-19,308,000 |
| Net Margin | -122.5% | -193.5% | -310.3% | -390.2% | -152.8% |
| EPS | $-2.62 | $-3.87 | $-5.43 | $-8.31 | $-19.83 |
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Visit WebsiteEarnings History & Surprises
PULMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | — | — | — | — |
Q4 2025 | Oct 16, 2025 | — | $-0.24 | — | — |
Q3 2025 | Aug 6, 2025 | — | $-0.42 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.50 | — | — |
Q1 2025 | Mar 21, 2025 | — | $-0.54 | — | — |
Q4 2024 | Nov 8, 2024 | — | $-0.71 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.87 | — | — |
Q2 2024 | May 10, 2024 | — | $0.23 | — | — |
Q1 2024 | Mar 28, 2024 | $-1.04 | $-0.57 | +45.2% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.05 | $-1.03 | +1.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.23 | $-1.04 | +15.4% | ✓ BEAT |
Q2 2023 | May 12, 2023 | — | $-1.22 | — | — |
Q1 2023 | Mar 30, 2023 | $-1.44 | $-1.14 | +20.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-1.51 | $-1.45 | +4.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.51 | $-1.36 | +9.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-1.41 | $-1.51 | -7.1% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-1.60 | $-2.43 | -51.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-1.40 | $-1.80 | -28.6% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-1.80 | $-1.40 | +22.2% | ✓ BEAT |
Latest News
Pulmatrix And Cullgen Agree To Waive 'No Solicitation' Clause In Merger Agreement, Granting Each Other Waivers To Explore Alternatives
➖ NeutralPulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
➖ NeutralPulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY
📈 PositiveFrequently Asked Questions about PULM
What is PULM's current stock price?
What is the analyst price target for PULM?
What sector is Pulmatrix, Inc. in?
What is PULM's market cap?
Does PULM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PULM for comparison